Terns Pharmaceuticals Files 8-K

Ticker: TERN · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1831363

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Terns Pharma filed an 8-K on 12/8/25 - check for updates.

AI Summary

On December 8, 2025, Terns Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing signals that Terns Pharmaceuticals is making disclosures to the SEC, which could pertain to significant company events or financial updates.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial data that would indicate immediate risk.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing?

The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided excerpt.

When was this 8-K report filed?

The report was filed as of December 08, 2025.

What is Terns Pharmaceuticals' principal executive office address?

The principal executive offices are located at 1065 East Hillsdale Blvd., Suite 100, Foster City, California, 94404.

What is the Commission File Number for Terns Pharmaceuticals?

The Commission File Number is 001-39926.

What is the SIC code for Terns Pharmaceuticals?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 2,157 words · 9 min read · ~7 pages · Grade level 16.5 · Accepted 2025-12-08 16:01:12

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, issued by Terns Pharmaceuticals, Inc. on December 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: December 8, 2025 By: /s/ Caryn McDowell Caryn McDowell Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing